TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04491981

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Encapsulated Glass Ionomer Cement
Description: Repair of restorations in primary molars using Encapsulated High Viscosity Glass Ionomer (RIVA Self Cure - SDI). No local anesthesia will be used. A portion of the former restoration and infected carious tissue can be removed if necessary, and then the restoration will be repaired with GIC (Glass Ionomer Cement).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Composite resin
Description: Repair of restorations in primary molars using composite resin (Filtek Bulk Fill- 3M ESPE.) No local anesthesia will be used.A portion of the former restoration and infected carious tissue can be removed if necessary, and then the restoration will be repaired with CR (composite resin).
Study: NCT06185439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prenatal Pilates Assisted Childbirth Preparation Training
Description: Training was given twice a week for two hours a day (one hour of theory, one An hour of exercise = 45 minutes of pregnant plates and 15 minutes of breathing exercises) total eight weeks.
Study: NCT05161845

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps and Rubella Combined Vaccine, Live
Description: 0.5ml of reconstituted vaccine per container. 0.5 ml per single human dose containing not less than 3.0 lg CCID50 of both live measles virus and rubella virus and 4.3 lg CCID50 of live mumps virus.
Study: NCT06014164

Intervention type: DIAGNOSTIC_TEST
Intervention: Interview
Description: An interview will be conducted to describe the experiences of people with psychiatric disorders who use psychedelic substances for therapeutic purposes
Study: NCT03526991

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulator (SCS)
Description: The SCS implantation technique consists of inserting epidural leads-containing multiple stimulating electrodes (8). Two leads will be implanted percutaneously into the epidural space.~The implantable pulse generator (IPG) is a neurostimulation system designed to deliver low-intensity electrical impulses. The system is intended to be used with leads and extensions that are compatible with the system. This neurostimulation system is indicated (FDA approved) as an aid in the management of chronic, intractable pain of the trunk and/or limbs. The intended use in this study is considered experimental.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulator (SCS)
Description: The SCS implantation technique consists of inserting epidural leads-containing multiple stimulating electrodes (8). Two leads will be implanted percutaneously into the epidural space.~The implantable pulse generator (IPG) is a neurostimulation system designed to deliver low-intensity electrical impulses. The system is intended to be used with leads and extensions that are compatible with the system. This neurostimulation system is indicated (FDA approved) as an aid in the management of chronic, intractable pain of the trunk and/or limbs. The intended use in this study is considered experimental.
Study: NCT05965427

Intervention type: OTHER
Intervention: No intervention
Description: Study is retrospective data collection only

Intervention type: OTHER
Intervention: No intervention
Description: Study is retrospective data collection only
Study: NCT05122689

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrate
Description: Dietary inorganic nitrate (0,12 mmol sodium-nitrate/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Dietary sodium-chloride (0,12 mmol sodium-chloride/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.
Study: NCT06087497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early mobilization
Description: Z stitch placement is standard of care to achieve vascular hemostasis after EP procedures which is followed by 4 hours of bedrest. In this study, we will compare patient satisfaction and bleeding complications with a shorter bedrest (1 hour instead of 4 hours)
Study: NCT04953741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate inhaled aerosol
Description: The study consists of two stages and include three groups. Three groups include: Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped Fluticasone propionate Inhaled Aerosol and continuation of montelukast once a day; Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug once a day; Stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug twice daily, and then Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day. The scheme of every group is divided into two stages. Only those whose asthma are well controlled at the end of the first phase will be allowed to proceed to the next phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate inhaled aerosol
Description: The study consists of two stages and include three groups. Three groups include: Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped Fluticasone propionate Inhaled Aerosol and continuation of montelukast once a day; Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug once a day; Stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug twice daily, and then Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day. The scheme of every group is divided into two stages. Only those whose asthma are well controlled at the end of the first phase will be allowed to proceed to the next phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate inhaled aerosol
Description: The study consists of two stages and include three groups. Three groups include: Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped Fluticasone propionate Inhaled Aerosol and continuation of montelukast once a day; Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug once a day; Stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug twice daily, and then Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day. The scheme of every group is divided into two stages. Only those whose asthma are well controlled at the end of the first phase will be allowed to proceed to the next phase.
Study: NCT04709497

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: viscotrabeculotomy (VT)
Description: viscotrabeculotomy (VT)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: visco-circumferential-suture-trabeculotomy (VCST) .
Description: visco-circumferential-suture-trabeculotomy (VCST)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined VT-Trabeculectomy with MMC (VT-Trab).
Description: combined VT-Trabeculectomy with MMC (VT-Trab).
Study: NCT06002659

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR20(NAP)-T
Description: Autologous CAR-T cells targeting CD20 and upon target recognition express and secrete NAP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: pre-conditioning chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: pre-conditioning chemotherapy
Study: NCT05265832

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Description: Endocapsular technique (Divide-and-conquer) and supracapsular technique (Subluxation) will be used equally.
Study: NCT05731128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: injection solution subcutaneous

Intervention type: DRUG
Group type: OTHER
Intervention: Dupilumab
Description: injection solution subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: injection solution subcutaneous
Study: NCT05863234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPMX-T003
Description: The therapeutic agent is administered continuously intravenously
Study: NCT05421065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 1 oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 1 oral dose
Study: NCT05169580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pociredir oral capsule(s)
Description: Participants will receive Pociredir
Study: NCT05155319

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: UFluA 20 µg each antigen/dose
Description: Low dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: UFluA 20 µg each antigen/dose
Description: Low dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: UFluA 60 µg each antigen/dose
Description: High Dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: UFluA 60 µg each antigen/dose
Description: High Dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06056557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VARIPULSE™ catheter ablation
Description: Subjects will arrive to the electrophysiology laboratory for their ablation procedure and will undergo preparation for the procedure per standard protocol.~The purpose of an ablation procedure is to scar or destroy the heart tissue causing the atrial fibrillation. The current FDA approved ablation treatments commonly use freezing, radio frequency, or laser, delivered through a catheter that is threaded through blood vessels to the heart, as the energy source to destroy the abnormal tissue.~The BWI IRE VARIPULSE ablation system used in this study uses a type of energy source called pulse field.~Pulse field ablation applies ultra-rapid (less than 1 second) electrical fields to the heart muscle to destroy the abnormal tissue. This type of energy is thought to safer and more effective at treating atrial fibrillation.~● For a lesion set that cannot be performed using the VARIPULSE catheter technology, a conventional FDA-approved RF ablation
Study: NCT05218174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Prescription
Description: In this prospective, randomized control trial, the investigators will compare functional exercise capacity, cognitive performance, and emotional well-being at baseline and following 2 conditions: (1) an 8-week exercise training program (intervention) or (2) no training program (control). Participants will be randomized using a 1:1 randomization scheme into either the intervention or control group. After 8 weeks, participants in the wait-list control group will begin the intervention for the next 8 weeks and activity undergone by participants first randomized into the intervention group will remain under observation.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise Prescription
Description: In this prospective, randomized control trial, the investigators will compare functional exercise capacity, cognitive performance, and emotional well-being at baseline and following 2 conditions: (1) an 8-week exercise training program (intervention) or (2) no training program (control). Participants will be randomized using a 1:1 randomization scheme into either the intervention or control group. After 8 weeks, participants in the wait-list control group will begin the intervention for the next 8 weeks and activity undergone by participants first randomized into the intervention group will remain under observation.
Study: NCT06030388

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: Both interventions (strength training and high intensity aerobic training) will be introduced with a 3-week adaptation period with lower loads (strength training) or intensity (aerobic training) followed by a 12-week period on the intended load/intensity. All participants in the intervention groups will be recommended to exercise three times per week (one hour per session) and in addition be active with everyday low-intensity physical activity. A structured and detailed training diary will be used in both groups to register frequency of each training session, as well as everyday physical activity. For the strength training, load and dose will also be registered for each training session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity aerobic training
Description: Both interventions (strength training and high intensity aerobic training) will be introduced with a 3-week adaptation period with lower loads (strength training) or intensity (aerobic training) followed by a 12-week period on the intended load/intensity. All participants in the intervention groups will be recommended to exercise three times per week (one hour per session) and in addition be active with everyday low-intensity physical activity. A structured and detailed training diary will be used in both groups to register frequency of each training session, as well as everyday physical activity. For the strength training, load and dose will also be registered for each training session.
Study: NCT06783101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of smart inhaler to enhance asthma inhaler proficiency
Description: The application of the smart inhaler technology to enhance asthma inhaler proficiency
Study: NCT06783270

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIL therapy
Description: Compared to traditional TIL-therapy, this study will include silencing of the PD-1 coding gene in the TILs using non-viral CRISPR-Cas9 prior to the rapid expansion protocol.
Study: NCT06787469

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resin Cement
Description: Bioactive self adhesive resin cement (SHOFU BeautiLink) used to cement indirect restorations to endodontically treated molars.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resin Cement
Description: Self adhesive resin cement
Study: NCT06784960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messages
Description: We will randomly assign participants in equal numbers to one of five theory-based HPV vaccine message conditions or an attention-matched control arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messages
Description: We will randomly assign participants in equal numbers to one of five theory-based HPV vaccine message conditions or an attention-matched control arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messages
Description: We will randomly assign participants in equal numbers to one of five theory-based HPV vaccine message conditions or an attention-matched control arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messages
Description: We will randomly assign participants in equal numbers to one of five theory-based HPV vaccine message conditions or an attention-matched control arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messages
Description: We will randomly assign participants in equal numbers to one of five theory-based HPV vaccine message conditions or an attention-matched control arm.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Messages
Description: We will randomly assign participants in equal numbers to one of five theory-based HPV vaccine message conditions or an attention-matched control arm.
Study: NCT06787989

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-CD19 cCAR T cells
Description: • BCMA-CD19 cCAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
Study: NCT06785259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention for Emotional Distress(MIED)
Description: Mindfulness Intervention for Emotional Distress (MIED) program provides standard audio instructions for mindfulness exercises, introduces the nature and law of anxiety, depression, and other emotions, the source of anxiety, depression, and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
Study: NCT06787261

Intervention type: OTHER
Group type: OTHER
Intervention: saliva sample
Description: saliva sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saliva sample
Description: saliva sample

Intervention type: OTHER
Group type: OTHER
Intervention: carious tissue samples
Description: carious tissue samples
Study: NCT06786897

Intervention type: OTHER
Intervention: Questionnaire and Physical Exam
Description: Questionnaires evaluating the expectations of patients in palliative situation, of paramedics and medical staff, concerning blood cell transfusions.
Study: NCT06786845

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment lege artis
Description: Adequate treatment of sleep disorders at Sleep clinic
Study: NCT04897438

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney allograft biopsy depending on donor-derived cell-free DNA levels
Description: Kidney allograft biopsy is performed, when absolute levels of donor-derived cell-free DNA are above 50 copies/ml
Study: NCT06354179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XR-tacrolimus QD + MMF BID then MMF QD
Description: Patients start on XR-Tacrolimus once daily (QD) and MMF twice daily (BID) as per the usual care. At 6 months post-transplantation (±1 month) MMF administration frequency will be switched from BID to QD, in the morning, at the same daily dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XR-tacrolimus QD + MMF BID
Description: Patients receive XR-tacrolimus once daily (QD) and MMF twice daily (BID) as per the usual care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCP-tacrolimus QD + MMF QD then MMF QD
Description: Patients start on LCP-Tacrolimus once daily (QD) and MMF twice daily (BID) as per usual care. At 6 months post-transplantation (±1 month), MMF administration frequency will be switched from BID to QD, in the morning, at the same daily dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LCP-tacrolimus QD + MMF BID
Description: Patients receive LCP-tacrolimus once daily (QD) and MMF twice daily (BID) as per the usual care.
Study: NCT04983108

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention. This is an observational Study
Study: NCT06385678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-4642
Description: administrated per dose level in which the patients are assigned

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-4642
Description: administrated per dose level in which the patients are assigned

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-4642
Description: administrated per dose level in which the patients are assigned

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: administrated per dose level in which the patients are assigned

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-9839
Description: administrated per dose level in which the patients are assigned

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection
Description: administered as prescribed by the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab Solution for Infusion
Description: administrated per dose level in which the patients are assigned
Study: NCT06310070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Printed Personalized Ostomy Appliance
Description: Study procedures will include getting your stoma scanned, receiving personalized ostomy appliances in the mail, receiving a personalized ostomy template, which will be printed using a 3D printer, in the mail, and completing a daily symptom diary along with a weekly survey for 4 weeks.3D printing is done using a machine that takes the 3D image from the computer and prints a replica of the image using plastic or other materials.
Study: NCT04970901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: IV infusion
Study: NCT06501573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGB-9768
Description: SGB-9768 for sc injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile normal saline (0.9% NaCl) for sc injection